E

Endo International PLC
LSE:0Y5F

Watchlist Manager
Endo International PLC
LSE:0Y5F
Watchlist
Price: 625.57 USD -0.41% Market Closed
Market Cap: 140.3B USD
Have any thoughts about
Endo International PLC?
Write Note

Endo International PLC
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Endo International PLC
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
E
Endo International PLC
LSE:0Y5F
Net Income (Common)
-$2.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
Net Income (Common)
-$159.7m
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Net Income (Common)
$463.2m
CAGR 3-Years
N/A
CAGR 5-Years
-5%
CAGR 10-Years
31%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Net Income (Common)
-$72.6m
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
-3%
Cosmo Pharmaceuticals NV
SIX:COPN
Net Income (Common)
€75.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-1%
Ovoca Bio PLC
LSE:OVB
Net Income (Common)
-€3.6m
CAGR 3-Years
-1%
CAGR 5-Years
-12%
CAGR 10-Years
8%
No Stocks Found

Endo International PLC
Glance View

Market Cap
147.1B USD
Industry
Pharmaceuticals

Endo International PLC is a specialty pharmaceutical company that operates at the intersection of innovation and necessity within the healthcare industry. Its primary business involves developing, manufacturing, and marketing both branded and generic pharmaceutical products. Endo thrives on a diversified portfolio that spans numerous therapeutic areas, including pain management, urology, orthopedics, and endocrinology. The company strategically positions itself by addressing unmet medical needs, often targeting niche markets where the competition is minimal, thus allowing for premium pricing and robust profit margins. Endo's revenue streams are driven by a blend of proprietary and generic drugs, with a significant portion coming from its well-known brands such as PERCOCET® and SUPPRELIN® LA. Its generics division supplements this by producing cost-effective versions of popular drugs, supporting market accessibility and appealing to cost-sensitive consumers and healthcare providers. By leveraging its research and development capabilities, Endo continues to enhance its product portfolio and explore new market opportunities. The company's growth is rooted in its ability to adapt to the ever-changing regulatory landscape, optimize its operations for efficiency, and forge strategic partnerships that enhance its market reach.

0Y5F Intrinsic Value
Not Available
E

See Also

What is Endo International PLC's Net Income (Common)?
Net Income (Common)
-2.9B USD

Based on the financial report for Dec 31, 2022, Endo International PLC's Net Income (Common) amounts to -2.9B USD.

What is Endo International PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
-377%

Over the last year, the Net Income (Common) growth was -377%.

Back to Top